Using a high-resolution proteomic pipeline, we achieved extensive CSF coverage and identified a 15-protein signature that distinguishes Aβ+/tau+, Aβ+/tau- and non-AD patients. The gene discussed is MAPT; the disease is Alzheimer disease.